VistaGen Therapeutics (VTGN) AI Stock Analysis

• Market Cap: $150.08M
• Dividend Yield: N/A
• Average Volume (3M): 515.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: -33.00%
• EPS Growth: 54.91%
• Country: US
• Employees: 48
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 39,495,453
• 10 Day Avg. Volume: 431,771
• 30 Day Avg. Volume: 515,460
• PEG Ratio: -0.15
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 157.98
• P/FCF Ratio: -1.82
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 71.57
• Enterprise Value/Gross Profit: 93.48
• Enterprise Value/Ebitda: -0.81
• 1Y Price Target: $15.50
• Price Target Upside: 288.47% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $4.00 ▲(0.25% Upside)

VistaGen Therapeutics' overall stock score is primarily impacted by its financial performance, which is currently weak due to consistent losses and negative cash flow. Despite this, positive developments in clinical trials and strategic corporate changes provide some optimism for future growth. The technical analysis and valuation metrics suggest caution, as the stock lacks strong momentum and is currently unprofitable.

Positive Factors

Leadership Expansion

The addition of Paul Edick to the board enhances VistaGen's strategic leadership, potentially accelerating regulatory approvals and commercial success.

Clinical Trial Progress

Progress in clinical trials for fasedienol positions VistaGen closer to market entry, addressing a significant unmet need in social anxiety disorder.

Strong Cash Position

A robust cash position provides VistaGen with the financial flexibility to fund ongoing R&D and potential NDA submissions, supporting long-term growth.

Negative Factors

Consistent Losses

Ongoing financial losses and negative cash flow could hinder VistaGen's ability to sustain operations without additional funding, impacting long-term viability.

Revenue Volatility

Volatile revenue growth reflects instability in financial performance, which may challenge VistaGen's ability to achieve consistent profitability.

Site Management Challenges

Challenges in site management during clinical trials could delay product development timelines, affecting VistaGen's strategic goals.

VistaGen Therapeutics Business Overview & Revenue Model

Company Description

VistaGen Therapeutics (VTGN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with psychiatric and neurological disorders. The company leverages its proprietary drug development platform, including its human-derived stem cell technology, to create new treatments aimed at addressing unmet medical needs in mental health, particularly in major depressive disorder and anxiety-related conditions. VistaGen's core product candidates include AV-101, a novel oral treatment for major depressive disorder, and other pipeline candidates targeting various central nervous system (CNS) disorders.

How the Company Makes Money

VistaGen Therapeutics primarily generates revenue through strategic partnerships, collaborations, and potential licensing agreements with larger pharmaceutical companies. These partnerships often involve shared development costs and milestone payments tied to clinical progress and regulatory approvals. Additionally, the company may receive royalties from the commercialization of successful products. As a clinical-stage entity, VistaGen does not yet have significant commercial revenues but relies on funding from equity offerings and grants to support its research and development activities until its products reach the market.

VistaGen Therapeutics Financial Statement Overview

Summary

VistaGen Therapeutics faces significant challenges with consistent losses and negative cash flow. However, a strong equity position and manageable debt levels provide some stability. While the revenue growth shows potential, the company must focus on improving operational efficiency and profitability to ensure long-term success.

Income Statement

The company's revenue growth has been volatile, with a significant drop this year compared to the previous year. Gross profit margin remains stable due to the low cost structure, but the net profit margin is severely negative. The EBIT and EBITDA margins are also deeply negative, indicating operational inefficiency. Despite these challenges, there is a slight increase in revenue compared to the previous year, showing potential for future growth.

Balance Sheet

VistaGen Therapeutics has a relatively low debt-to-equity ratio, indicating a conservative capital structure. However, the return on equity is negative, impacted by consistent net losses. The equity ratio is strong, suggesting financial stability and a solid foundation for future growth. Despite these strengths, the company needs to improve profitability to leverage its equity effectively.

Cash Flow

The company's free cash flow is negative but shows improvement from the previous year, suggesting progress towards better cash management. Operating cash flow remains negative, but the ratio to net income indicates that cash losses are less severe than income losses. Continued focus on reducing cash burn is crucial for future financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	721.00K	486.00K	1.06M	-227.00K	1.11M	1.09M
Gross Profit	552.00K	486.00K	1.06M	-227.00K	1.11M	1.09M
EBITDA	-63.45M	-55.34M	-32.45M	-58.74M	-47.05M	-17.44M
Net Income	-62.24M	-51.42M	-29.36M	-59.25M	-47.76M	-17.93M
Balance Sheet
Total Assets	80.93M	84.34M	123.65M	21.09M	74.64M	108.28M
Cash, Cash Equivalents and Short-Term Investments	77.17M	80.48M	119.17M	16.64M	68.14M	103.11M
Total Debt	1.86M	1.51M	2.12M	2.71M	3.04M	3.72M
Total Liabilities	14.59M	13.95M	9.37M	9.01M	9.93M	16.30M
Stockholders Equity	66.34M	70.39M	114.29M	12.08M	64.72M	91.98M
Cash Flow
Free Cash Flow	-53.09M	-42.29M	-25.87M	-49.93M	-45.46M	-12.35M
Operating Cash Flow	-52.95M	-42.10M	-25.81M	-49.72M	-45.26M	-12.07M
Investing Cash Flow	-777.00K	-13.15M	-61.00K	-740.00K	-200.40K	-275.40K
Financing Cash Flow	32.26M	3.21M	128.40M	-1.04M	10.48M	114.10M

VistaGen Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTGN, the sentiment is Positive. The current price of 3.99 is below the 20-day moving average (MA) of 4.36, below the 50-day MA of 4.16, and above the 200-day MA of 3.03, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 50.15 is Neutral, neither overbought nor oversold. The STOCH value of 60.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTGN.

VistaGen Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	56 Neutral	$99.70M	―	-60.06%	―	946.61%	-11.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPRO	48 Neutral	$130.71M	―	-95.29%	―	-67.38%	-1076.54%
VTGN	48 Neutral	$150.08M	―	―	―	-33.00%	54.91%
IKT	46 Neutral	$118.48M	-1.46	-131.71%	―	-100.00%	79.01%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
MGNX	41 Neutral	$89.19M	―	-81.13%	―	-9.70%	23.23%

VistaGen Therapeutics Corporate Events

VistaGen Therapeutics Appoints New CFO Nick B. Tressler

On December 1, 2025, Vistagen appointed Nick B. Tressler as Chief Financial Officer and Treasurer, succeeding Shawn K. Singh in his interim role. Tressler, with over 20 years of experience in financial leadership within the life sciences industry, is expected to contribute significantly to Vistagen’s strategic growth and transformation. His appointment comes with a comprehensive compensation package, including stock options, reflecting the company’s commitment to advancing its financial strategies and enhancing shareholder value.

VistaGen Completes Patient Phase in Key Clinical Trial

On November 3, 2025, Vistagen Therapeutics announced the completion of the patient participation phase in the PALISADE-3 Phase 3 clinical trial for fasedienol, aimed at treating social anxiety disorder. This milestone is significant as it brings the company closer to potentially offering the first acute treatment for social anxiety disorder, affecting over 30 million individuals in the U.S. The results from this trial, along with the ongoing PALISADE-4 trial, could support a New Drug Application submission to the FDA, marking a pivotal step in Vistagen’s efforts to address this prevalent mental health condition.

VistaGen Therapeutics Appoints Paul R. Edick to Board

On October 27, 2025, Vistagen Therapeutics appointed Paul R. Edick to its Board of Directors, where he will also serve on the Audit and Compensation Committees. Mr. Edick, with his extensive industry experience, is expected to contribute significantly to Vistagen’s strategic growth and governance as the company advances its innovative solutions for mental health. His appointment comes at a pivotal moment for Vistagen, as they prepare for their next phase of strategic growth, following the retirement of Dr. Jerry Gin from the Board.

VistaGen Therapeutics CFO Resignation Announced

VistaGen Therapeutics announced the resignation of its Chief Financial Officer, Cynthia L. Anderson, effective October 15, 2025. The company is searching for her successor and plans to retain her as a consultant to ensure a smooth transition. Additionally, at the 2025 Annual Meeting of Stockholders held on September 9, 2025, VistaGen’s stockholders elected six directors to the Board, approved executive compensation, and ratified KPMG LLP as the independent auditor for the fiscal year ending March 31, 2026.